Low insulin levels and low body mass numbers may improve prostate cancer survival rates, according to a recent study.
Fort Worth, TX (WiredPRNews.com)—Having a low insulin levels and not being obese may be more important than chemotherapy, according to a recent study, when it comes to defeating prostate cancer.
According to an October 6, 2008 Health Day article by Amanda Gardner that appeared in Yahoo.com’s news page, a Canadian oncology professor discovered that prostate cancer patients with body mass indexes (BMI) over 30 were 2.5 times more likely to die from the disease than patients with BMIs below 25.
The body mass index shows the fat-to-muscle ratio and is a more accurate measure of health than simple body weight-to-height ratios.
Dr. Michael Pollack of Montreal’s McGill University served as a senior study author of the results, which appear in the November 2008 issue of The Lancet Oncology, according to the Health Day article. The study, conducted over a 24- year period, followed the lives of 2,500 men and showed that obesity and high insulin levels dramatically increased the likelihood of death from prostate cancer.
According to the article, researchers believe that prostate cancer cells are accepting the insulin hormone via their own insulin receptors. The findings are so significant that, according to the article, some pharmaceutical companies are testing drugs that target insulin signaling.
The findings of the study strongly suggest that obesity has a massive impact on not just prostate cancer survival, but of cancer risk in general.